Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Clinical Editor's comments (September 2017)
Dr Hayley Willacy would like to make you aware that people with moderate to severe plaque psoriasis can now receive dimethyl fumarate (Skilarence®) as a licensed oral treatment option for those needing systemic therapy [ 19 ] . It can be prescribed as first-line induction therapy and long-term maintenance treatment. Dimethyl fumarate as Fumaderm® is already used as an unlicensed product in the UK. The anti-inflammatory and immunomodulating effects of dimethyl fumarate are not fully understood but are thought to involve a shift in T helper cells from the Th1 and Th17 phenotypes to the Th2 phenotype, with a resultant decrease in the production of inflammatory cytokines and inhibition of keratinocyte proliferation.
The first sulfonamide and the first systemically active antibacterial drug, Prontosil , was developed by a research team led by Gerhard Domagk in 1932 or 1933 at the Bayer Laboratories of the IG Farben conglomerate in Germany,    for which Domagk received the 1939 Nobel Prize in Physiology or Medicine.  Sulfanilamide, the active drug of Prontosil, was not patentable as it had already been in use in the dye industry for some years.  Prontosil had a relatively broad effect against Gram-positive cocci , but not against enterobacteria . Research was stimulated apace by its success. The discovery and development of this sulfonamide drug opened the era of antibacterials.